| Gene symbol | TGFB2 | Synonyms | G-TSF, LDS4, TGF-beta2 | Type of gene | protein-coding |
| Chromosome | 1 | Map location | 1q41 | dbXrefs | |
| Description | transforming growth factor beta 2 | ||||
| GTO ID | GTC1304 |
| Trial ID | NCT00761280 |
| Disease | Anaplastic Astrocytoma |
| Altered gene | TGFB2 |
| Therapeutic/Target gene | Target gene |
| Therapy | ASO |
| Treatment | Trabedersen|AP 12009 |
| Phase | Phase3 |
| Recruitment status | Terminated |
| Title | Efficacy and Safety of AP 12009 in Adult Patients With Recurrent or Refractory Anaplastic Astrocytoma or Secondary Glioblastoma as Compared to Standard Chemotherapy Treatment: A Randomized, Actively Controlled, Open Label Clinical Phase III Study. |
| Year | 2009 |
| Country | Germany |
| Company sponsor | Aegera Therapeutics Inc. |
| Other ID(s) | AP12009-G005 |
| Vector information | |||
|
|||
| Cohort 1 | |||||
|
|||||